| Biomarker ID | 1452 |
| PMID | 24976077 |
| Year | 2014 |
| Biomarker | miR-361-3p + miR-361-3p+ mir-221+ mir-203 + mir-133b |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Prostate Secretion Samples |
| Subjects | Humans |
| Regulation | Downregulated in PCa [miR-361-3p; miR-361-3p; mir-221; mir-133b]; Upregulated in PCa: [mir-203] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | Prostate secretion samples (PSS) from 23 PCa and 25 benign prostate hyperplasia (BPH) patients were obtained |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.95 |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | 4 patients from the cohort were selected for microarray analysis to confirm the results |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | miR-361-3p, mir-221, mir-203, mir-133b |